Pacific Biosciences of California, Inc. Stock
Stocks
PACB
US69404D1081
Advanced Medical Equipment & Technology
|
Market Closed -
Nasdaq
06:00:00 03/10/26 am AEST
|
5-day change | 1st Jan Change | ||
| 2.540 USD | +1.20% |
|
+56.79% | +35.83% |
| Market Cap | 790M 701M 655M 597M 1.13B 75.9B 1.14B 7.92B 3.07B 38.8B 2.96B 2.9B 125B | P/E 2026 * |
-5.74x | P/E 2027 * | -5.38x |
|---|---|---|---|---|---|
| Enterprise Value | 1.26B 1.12B 1.04B 951M 1.79B 121B 1.81B 12.63B 4.89B 61.83B 4.72B 4.62B 198B | EV / Sales 2026 * |
7.92x | EV / Sales 2027 * | 7.15x |
| Free-Float |
91.09% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| PACB | Delayed | |
CBOE
| PACB | Real-time | |
|
Börse Stuttgart
| P09 | Delayed | |
|
Tradegate
| P09 | Real-time | |
|
Mexican S.E.
| PACB * | End-of-day quote | |
|
Boerse Muenchen
| P09 | Real-time | |
|
Deutsche Boerse AG
| P09 | Delayed |
Last Transcript: Pacific Biosciences of California, Inc.
| 1 day | +1.20% | ||
| 1 week | +56.79% | ||
| Current month | +7.17% | ||
| 1 month | +88.15% | ||
| 3 months | +51.19% | ||
| 6 months | +89.55% | ||
| Current year | +35.83% |
| 1 week | 1.63 |  | 2.64 |
| 1 month | 1.25 | | 2.64 |
| Current year | 1.07 | | 2.73 |
| 1 year | 1.07 | | 2.73 |
| 3 years | 0.85 | | 10.65 |
| 5 years | 0.85 | | 31.1 |
| 10 years | 0.85 | | 53.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark van Oene
CEO | Chief Executive Officer | 53 | 05/08/2026 |
Jim Gibson
DFI | Director of Finance/CFO | 57 | 31/03/2025 |
Jonas Korlach
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2012 |
| Director | Title | Age | Since |
|---|---|---|---|
Bill Ericson
BRD | Director/Board Member | 67 | 01/01/2004 |
Randy Livingston
BRD | Director/Board Member | 72 | 01/01/2009 |
Marshall Mohr
BRD | Director/Board Member | 69 | 18/01/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 17/8/26 | Sell | Chief Executive Officer | -26,911 | 0.0087% | ||
| 10/8/26 | Free | Chief Executive Officer | 2,457,018 | 0.7911% | ||
| 3/6/26 | Free | Chairman | 223,492 | 0.0720% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.20% | +56.79% | +70.47% | -68.29% | 790M | |
| +0.35% | -2.99% | +20.52% | +30.32% | 242B | |
| +1.09% | -4.65% | -0.43% | -0.93% | 150B | |
| -2.32% | -3.27% | -13.35% | +35.02% | 138B | |
| -1.46% | -3.01% | -56.23% | -17.36% | 61.74B | |
| -0.05% | -1.32% | +10.48% | +19.48% | 49.08B | |
| -1.02% | -3.62% | -22.87% | -21.93% | 47.43B | |
| +0.66% | -2.90% | +18.46% | +50.25% | 47.3B | |
| -3.05% | -2.62% | -7.75% | +36.34% | 44.25B | |
| -0.08% | -1.92% | +29.48% | +58.80% | 41.78B | |
| Average | -0.22% | +3.43% | +4.88% | +12.17% | 82.34B | |
| Weighted average by Cap. | +0.03% | -2.92% | +1.01% | +20.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 159M 141M 132M 120M 226M 15.26B 228M 1.59B 617M 7.8B 596M 583M 25.04B | 184M 163M 152M 139M 262M 17.66B 264M 1.84B 715M 9.03B 690M 675M 28.98B |
| Net income | -141M -125M -117M -107M -201M -13.55B -203M -1.41B -548M -6.93B -529M -518M -22.23B | -145M -129M -120M -110M -207M -13.95B -209M -1.46B -564M -7.13B -545M -533M -22.88B |
| Net Debt | 469M 416M 389M 354M 668M 45.06B 674M 4.7B 1.82B 23.03B 1.76B 1.72B 73.92B | 525M 466M 435M 396M 748M 50.43B 755M 5.26B 2.04B 25.78B 1.97B 1.93B 82.73B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | USD 2.540 | +1.20% | 26,011,242 |
| 01/10/26 | USD 2.510 | +5.91% | 35,866,101 |
| 30/09/26 | USD 2.370 | +29.51% | 80,386,307 |
| 29/09/26 | USD 1.830 | +7.02% | 17,423,893 |
| 28/09/26 | USD 1.710 | +5.56% | 21,281,906 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PACB Stock
Select your edition
All financial news and data tailored to specific country editions
